News from oncogenex pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 19, 2014, 08:00 ET

OncoGenex Announces Results from the Phase 2 Borealis-1™ Trial of Apatorsen in the Treatment of Metastatic Bladder Cancer

Exploratory Analysis Shows Addition of 600mg Apatorsen to Standard of Care Chemotherapy Resulted in 50 Percent Reduction in Risk of Death in...

Dec 16, 2014, 06:30 ET

OncoGenex Announces Completion of Patient Enrollment in the Rainier™ Clinical Trial Evaluating Apatorsen in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic Cancer

 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that patient enrollment has been completed in the Rainier™ clinical...

Nov 17, 2014, 06:30 ET

OncoGenex Pharmaceuticals to Present at the Stifel 2014 Healthcare Conference

 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, President and Chief Executive Officer, will provide a...

Oct 30, 2014, 16:01 ET

OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2014

 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided a summary of clinical developments and announced third quarter 2014 financial...

Oct 16, 2014, 06:30 ET

OncoGenex to Report Financial Results for Third Quarter 2014 on October 30, 2014

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's third quarter 2014 financial results will be released on...

Sep 16, 2014, 06:30 ET
Aug 21, 2014, 16:01 ET

OncoGenex Announces Update on Phase 3 ENSPIRIT Trial Evaluating Custirsen in Advanced Non-Small Cell Lung Cancer

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Phase 3 ENSPIRIT trial, evaluating custirsen in the treatment of non-small...

Aug 07, 2014, 16:01 ET

OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2014

 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided a summary of clinical developments and announced second quarter 2014 financial...

Aug 07, 2014, 06:30 ET

OncoGenex Pharmaceuticals Announces Appointment of John A. Bencich as Vice President and Chief Financial Officer

 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced the appointment of John A. Bencich as Vice President and Chief Financial...

Jul 24, 2014, 06:30 ET

OncoGenex to Report Financial Results for Second Quarter 2014 on August 7, 2014

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's second quarter 2014 financial results will be released on...

Jul 01, 2014, 06:30 ET

OncoGenex Announces Cedar™ Clinical Trial Evaluating Apatorsen in Combination with Chemotherapy in Advanced Squamous Cell Lung Cancer is Now Open for Enrollment

 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced initiation of the Cedar™ clinical trial, an investigator-sponsored,...

Jun 26, 2014, 18:00 ET

OncoGenex Pharmaceuticals Announces Pricing of $24 Million Underwritten Registered Direct Offering

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that it has priced an underwritten registered direct offering, which is expected to...

Apr 30, 2014, 16:00 ET

OncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2014

 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided a summary of clinical developments and anticipated near-term milestones and...

Apr 28, 2014, 07:15 ET

OncoGenex to Report Financial Results for First Quarter 2014 on April 30, 2014

 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's first quarter 2014 financial results will be released on...

Apr 28, 2014, 07:10 ET

OncoGenex Announces Top-Line Survival Results of Phase 3 SYNERGY Trial Evaluating Custirsen for Metastatic Castrate-Resistant Prostate Cancer

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced results from the Phase 3 SYNERGY trial. Top-line survival results indicate that the...

Apr 23, 2014, 06:00 ET
Mar 11, 2014, 16:00 ET

OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2013

 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided a summary of clinical developments and anticipated near-term milestones and...

Feb 25, 2014, 06:30 ET

OncoGenex to Report Financial Results for Fourth Quarter and Year-Ended 2013 on March 11, 2014

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's fourth quarter and year-ended 2013 financial results will be...

Feb 11, 2014, 06:00 ET

OncoGenex Announces Target Number of Events Reached in Phase 3 SYNERGY Trial of Custirsen in Metastatic Castrate-Resistant Prostate Cancer

 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that the pre-specified number of events required for final analysis of the...

Feb 06, 2014, 06:30 ET

OncoGenex to Present at Leerink Global Healthcare Investor Conference

 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, President and Chief Executive Officer, will provide a...